Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301


Assessing scientists for hiring, promotion, and tenure.

Moher D, Naudet F, Cristea IA, Miedema F, Ioannidis JPA, Goodman SN.

PLoS Biol. 2018 Mar 29;16(3):e2004089. doi: 10.1371/journal.pbio.2004089. eCollection 2018 Mar.


Fewer numbers, better science.

Benedictus R, Miedema F, Ferguson MW.

Nature. 2016 Oct 27;538(7626):453-455. doi: 10.1038/538453a. No abstract available.


Quantification of naive and memory T-cell turnover during HIV-1 infection.

Vrisekoop N, Drylewicz J, Van Gent R, Mugwagwa T, Van Lelyveld SF, Veel E, Otto SA, Ackermans MT, Vermeulen JN, Huidekoper HH, Prins JM, Miedema F, de Boer RJ, Tesselaar K, Borghans JA.

AIDS. 2015 Oct 23;29(16):2071-80. doi: 10.1097/QAD.0000000000000822.


Differential characteristics of cytotoxic T lymphocytes restricted by the protective HLA alleles B*27 and B*57 in HIV-1 infection.

Schellens IM, Spits HB, Navis M, Westerlaken GH, Nanlohy NM, Coffeng LE, Kootstra N, Miedema F, Schuitemaker H, Borghans JA, van Baarle D.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):236-45. doi: 10.1097/QAI.0000000000000324.


Overcoming language barriers for pediatric surgical patients and their family members.

Weldon JM, Langan K, Miedema F, Myers J, Oakie A, Walter E.

AORN J. 2014 May;99(5):616-29; quiz 630-2. doi: 10.1016/j.aorn.2014.02.005. No abstract available.


Immune activation and collateral damage in AIDS pathogenesis.

Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA.

Front Immunol. 2013 Sep 26;4:298. doi: 10.3389/fimmu.2013.00298. Review.


Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans.

den Braber I, Mugwagwa T, Vrisekoop N, Westera L, Mögling R, de Boer AB, Willems N, Schrijver EH, Spierenburg G, Gaiser K, Mul E, Otto SA, Ruiter AF, Ackermans MT, Miedema F, Borghans JA, de Boer RJ, Tesselaar K.

Immunity. 2012 Feb 24;36(2):288-97. doi: 10.1016/j.immuni.2012.02.006.


Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic.

Schellens IM, Navis M, van Deutekom HW, Boeser-Nunnink B, Berkhout B, Kootstra N, Miedema F, Keşmir C, Schuitemaker H, van Baarle D, Borghans JA.

AIDS. 2011 Sep 10;25(14):1691-700. doi: 10.1097/QAD.0b013e32834981b3.


Long-term restoration of the human T-cell compartment after thymectomy during infancy: a role for thymic regeneration?

van Gent R, Schadenberg AW, Otto SA, Nievelstein RA, Sieswerda GT, Haas F, Miedema F, Tesselaar K, Jansen NJ, Borghans JA.

Blood. 2011 Jul 21;118(3):627-34. doi: 10.1182/blood-2011-03-341396. Epub 2011 May 31.


Grand Challenges in the Immunology of HIV and AIDS.

Miedema F.

Front Immunol. 2011 Sep 23;2:20. doi: 10.3389/fimmu.2011.00020. eCollection 2011. No abstract available.


Immunological analysis of treatment interruption after early highly active antiretroviral therapy.

Schellens IM, Pogany K, Westerlaken GH, Borghans JA, Miedema F, van Valkengoed IG, Kroon FP, Lange JM, Brinkman K, Prins JM, van Baarle D.

Viral Immunol. 2010 Dec;23(6):609-18. doi: 10.1089/vim.2010.0062.


In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow.

van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JA, Vrisekoop N, Ackermans MA, Ruiter AF, Wittebol S, Eldering E, van Oers MH, Tesselaar K, Kersten MJ, Miedema F.

Cancer Res. 2008 Dec 15;68(24):10137-44. doi: 10.1158/0008-5472.CAN-08-2325.


A brief history of HIV vaccine research: stepping back to the drawing board?

Miedema F.

AIDS. 2008 Sep 12;22(14):1699-703. doi: 10.1097/QAD.0b013e3283021a61. Review.


HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.


Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.

Schellens IM, Borghans JA, Jansen CA, De Cuyper IM, Geskus RB, van Baarle D, Miedema F.

PLoS One. 2008 Jul 23;3(7):e2745. doi: 10.1371/journal.pone.0002745.


Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging.

Vrisekoop N, van Gent R, de Boer AB, Otto SA, Borleffs JC, Steingrover R, Prins JM, Kuijpers TW, Wolfs TF, Geelen SP, Vulto I, Lansdorp P, Tesselaar K, Borghans JA, Miedema F.

J Immunol. 2008 Jul 15;181(2):1573-81.


Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool.

Vrisekoop N, den Braber I, de Boer AB, Ruiter AF, Ackermans MT, van der Crabben SN, Schrijver EH, Spierenburg G, Sauerwein HP, Hazenberg MD, de Boer RJ, Miedema F, Borghans JA, Tesselaar K.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6115-20. doi: 10.1073/pnas.0709713105. Epub 2008 Apr 17.


Growth hormone resurrects adult human thymus during HIV-1 infection.

Tesselaar K, Miedema F.

J Clin Invest. 2008 Mar;118(3):844-7. doi: 10.1172/JCI35112.


A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.

Navis M, Schellens IM, van Swieten P, Borghans JA, Miedema F, Kootstra NA, van Baarle D, Schuitemaker H.

J Infect Dis. 2008 Mar 15;197(6):871-9. doi: 10.1086/528695.


Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals.

Vermeulen JN, Prins JM, Bunnik E, Hack CE, Jurriaans S, Miedema F, Lange JM, Schuitemaker H.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1348-53. doi: 10.1089/aid.2006.0210.


An unanticipated lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction programs.

Schellens IM, Keşmir C, Miedema F, van Baarle D, Borghans JA.

AIDS. 2008 Jan 2;22(1):33-7.


Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment.

Koot M, van 't Wout AB, Miedema F, Schuitemaker H.

BioDrugs. 1997 Oct;8(4):243-9. No abstract available.


Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.

Visser J, Nijman HW, Hoogenboom BN, Jager P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, van der Zee AG, Daemen T.

Clin Exp Immunol. 2007 Nov;150(2):199-209.


The HIV RNA setpoint theory revisited.

Geskus RB, Prins M, Hubert JB, Miedema F, Berkhout B, Rouzioux C, Delfraissy JF, Meyer L.

Retrovirology. 2007 Sep 21;4:65.


Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection.

Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, Kootstra N, Schuitemaker H.

J Immunol. 2007 Sep 1;179(5):3133-43.


Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation.

Casula M, Vrisekoop N, Wit FW, de Baar MP, de Ronde A, Miedema F, Reiss P.

J Infect Dis. 2007 Aug 1;196(3):371-6. Epub 2007 Jun 15.


Shift of CMV-specific CD4+ T-cells to the highly differentiated CD45RO-CD27- phenotype parallels loss of proliferative capacity and precedes progression to HIV-related CMV end-organ disease.

Bronke C, Jansen CA, Westerlaken GH, De Cuyper IM, Miedema F, Tesselaar K, van Baarle D.

Clin Immunol. 2007 Aug;124(2):190-9. Epub 2007 Jun 6.


Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.

Choudhary SK, Vrisekoop N, Jansen CA, Otto SA, Schuitemaker H, Miedema F, Camerini D.

J Virol. 2007 Aug;81(16):8838-42. Epub 2007 May 30.


HIV-1 Subtype C gag-specific T-cell responses in relation to human leukocyte antigens in a diverse population of HIV-infected Ethiopians.

Tsegaye A, Ran L, Wolday D, Petros B, Dorigo W, Piriou E, Messele T, Sanders E, Tilahun T, Eshetu D, Schuitemaker H, Coutinho RA, Miedema F, Borghans J, van Baarle D.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):389-400.


CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.

Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, Miedema F, Reiss P, Lange JM, de Wolf F; ATHENA, Netherlands National Observational Cohort Study.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92.


Stable pattern of HIV-1 subtype C Gag-specific T-cell responses coincides with slow rate of CD4 T-cell decline in HIV-infected Ethiopians.

Tsegaye A, Ran L, Wolday D, Petros B, Nanlohy NM, Meles H, Girma M, Hailu E, Borghans J, Miedema F, van Baarle D.

AIDS. 2007 Jan 30;21(3):369-72.


Bar-coded patient ID: review an organizational approach to vendor selection.

Wickham V, Miedema F, Gamerdinger K, DeGooyer J.

Nurs Manage. 2006 Dec;37(12):22-6. No abstract available.


Tuberculin skin test conversion and reactivity rates among adults with and without human immunodeficiency virus in urban settings in Ethiopia.

Tegbaru B, Wolday D, Messele T, Legesse M, Mekonnen Y, Miedema F, van Baarle D.

Clin Vaccine Immunol. 2006 Jul;13(7):784-9.


Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency.

Borghans JA, Bredius RG, Hazenberg MD, Roelofs H, Jol-van der Zijde EC, Heidt J, Otto SA, Kuijpers TW, Fibbe WE, Vossen JM, Miedema F, van Tol MJ.

Blood. 2006 Jul 15;108(2):763-9.


Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.

Jansen CA, Piriou E, De Cuyper IM, van Dort K, Lange JM, Miedema F, van Baarle D.

Antivir Ther. 2006;11(1):105-16.


HIV-specific CD4+ T cells and viremia: who's in control?

Jansen CA, van Baarle D, Miedema F.

Trends Immunol. 2006 Mar;27(3):119-24. Epub 2006 Feb 3.


T cell dynamics and protective immunity in HIV infection: a brief history of ideas.

Miedema F.

Curr Opin HIV AIDS. 2006 Jan;1(1):1-2. doi: 10.1097/01.COH.0000194104.35686.d7. No abstract available.


Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients.

Vrisekoop N, Sankatsing SU, Jansen CA, Roos MT, Otto SA, Schuitemaker H, Lange JM, Prins JM, Miedema F.

AIDS Res Hum Retroviruses. 2005 Dec;21(12):991-6.


Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.

Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Bungener L, de Vries-Idema J, Nijman H, Miedema F, Daemen T, van der Zee A.

Int J Cancer. 2006 May 15;118(10):2529-37.


CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals.

Geels MJ, Jansen CA, Baan E, De Cuyper IM, van Schijndel GJ, Schuitemaker H, Goudsmit J, Pollakis G, Miedema F, Paxton WA, van Baarle D.

Virology. 2006 Feb 5;345(1):209-19. Epub 2005 Oct 21.


Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection.

Koning FA, Otto SA, Hazenberg MD, Dekker L, Prins M, Miedema F, Schuitemaker H.

J Immunol. 2005 Nov 1;175(9):6117-22.


Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study.

Jansen CA, De Cuyper IM, Hooibrink B, van der Bij AK, van Baarle D, Miedema F.

Blood. 2006 Feb 15;107(4):1427-33. Epub 2005 Oct 18.


T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani.

Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, Kager PA.

Clin Immunol. 2005 Nov;117(2):182-91. Epub 2005 Aug 25.


Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers.

Mekonnen Y, Geskus RB, Hendriks JC, Messele T, Borghans J, Miedema F, Wolday D, Coutinho RA, Dukers NH.

J Infect Dis. 2005 Sep 1;192(5):739-48. Epub 2005 Jul 22.


Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.

Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.

J Immunol. 2005 Aug 1;175(3):2010-7.


Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.

Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D.

Blood. 2005 Nov 1;106(9):3166-74. Epub 2005 Jul 12.


Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, Lange JM, van Baarle D, Miedema F.

AIDS. 2005 Jul 22;19(11):1145-54.


Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus.

Kloosterboer N, Groeneveld PH, Jansen CA, van der Vorst TJ, Koning F, Winkel CN, Duits AJ, Miedema F, van Baarle D, van Rij RP, Brinkman K, Schuitemaker H.

Virology. 2005 Aug 15;339(1):70-80.


Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.

Wolday D, Tegbaru B, Kassu A, Messele T, Coutinho R, van Baarle D, Miedema F.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):265-71.


High plasma HIV load in the CRF01-AE outbreak among injecting drug users in Finland.

Kivelä PS, Krol A, Salminen MO, Geskus RB, Suni JI, Anttila VJ, Liitsola K, Zetterberg V, Miedema F, Berkhout B, Coutinho RA, Ristola MA.

Scand J Infect Dis. 2005;37(4):276-83.


Supplemental Content

Loading ...
Support Center